| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-11 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.24 | 7e-11 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.19 | 7e-11 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.25 | 4e-10 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-09 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.22 | 5e-09 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 6e-09 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-08 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-08 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-08 |